• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

抗-HBe阳性慢性活动性乙型肝炎的长期随访

Long-term follow-up of anti-HBe-positive chronic active hepatitis B.

作者信息

Fattovich G, Brollo L, Alberti A, Pontisso P, Giustina G, Realdi G

机构信息

Istituto di Medicina Clinica, Università di Padova, Italy.

出版信息

Hepatology. 1988 Nov-Dec;8(6):1651-4. doi: 10.1002/hep.1840080630.

DOI:10.1002/hep.1840080630
PMID:3192180
Abstract

Twenty-eight patients with chronic active hepatitis without cirrhosis who were positive for hepatitis B surface antigen and antibody to hepatitis B e antigen were followed for 1 to 15 years (mean 6.6 years) and underwent follow-up biopsy. At presentation, 12 of the 28 patients (43%) had hepatitis B virus DNA in serum, 10 (36%) had serologic evidence of hepatitis delta virus infection and 6 (21%) had no serologic markers of either hepatitis B virus replication or hepatitis delta virus infection. During follow-up, 15 (54%) patients developed active cirrhosis, including eight patients with hepatitis delta virus infection and five with hepatitis B virus DNA in serum. In seven (47%) of the 15 patients, cirrhosis developed within the first 2 years; all seven patients had bridging necrosis in the first liver biopsy, and five of these were infected with hepatitis delta virus. The remaining 13 (46%) patients did not develop cirrhosis during follow-up and showed either unchanged features of chronic active hepatitis (seven cases) or histologic improvement to chronic persistent hepatitis (five cases) or to normal liver (one case). In conclusion, the prognosis of anti-HBe-positive patients with chronic hepatitis B is poor, as 54% of the cases developed cirrhosis during a mean histologic follow-up period of 4.5 years, mainly in association with hepatitis delta virus infection or continuing hepatitis B virus replication.

摘要

对28例无肝硬化的慢性活动性乙型肝炎患者进行了随访,这些患者乙肝表面抗原和乙肝e抗原抗体均呈阳性,随访时间为1至15年(平均6.6年),并接受了随访活检。就诊时,28例患者中有12例(43%)血清中存在乙肝病毒DNA,10例(36%)有丁型肝炎病毒感染的血清学证据,6例(21%)既无乙肝病毒复制的血清学标志物,也无丁型肝炎病毒感染的血清学标志物。随访期间,15例(54%)患者发展为活动性肝硬化,其中8例为丁型肝炎病毒感染患者,5例血清中有乙肝病毒DNA。在这15例患者中的7例(47%)在最初2年内发展为肝硬化;所有7例患者在首次肝活检时均有桥接坏死,其中5例感染了丁型肝炎病毒。其余13例(46%)患者在随访期间未发展为肝硬化,表现为慢性活动性肝炎特征未改变(7例)或组织学改善为慢性持续性肝炎(5例)或正常肝脏(1例)。总之,抗-HBe阳性的慢性乙型肝炎患者预后较差,因为在平均4.5年的组织学随访期内,54%的病例发展为肝硬化,主要与丁型肝炎病毒感染或乙肝病毒持续复制有关。

相似文献

1
Long-term follow-up of anti-HBe-positive chronic active hepatitis B.抗-HBe阳性慢性活动性乙型肝炎的长期随访
Hepatology. 1988 Nov-Dec;8(6):1651-4. doi: 10.1002/hep.1840080630.
2
Clinical, virologic and histologic outcome following seroconversion from HBeAg to anti-HBe in chronic hepatitis type B.慢性乙型肝炎患者HBeAg血清学转换为抗-HBe后的临床、病毒学及组织学转归
Hepatology. 1986 Mar-Apr;6(2):167-72. doi: 10.1002/hep.1840060203.
3
Chronic hepatitis in HBsAg carriers with serum HBV-DNA and anti-HBe.血清中存在乙肝病毒脱氧核糖核酸(HBV-DNA)且抗-HBe阳性的乙肝表面抗原(HBsAg)携带者的慢性肝炎
Gastroenterology. 1986 May;90(5 Pt 1):1268-73. doi: 10.1016/0016-5085(86)90395-1.
4
Long-term evolution of chronic hepatitis B in children with antibody to hepatitis B e antigen.
J Pediatr. 1990 Apr;116(4):552-5. doi: 10.1016/s0022-3476(05)81601-4.
5
Long-term outcome of chronic type B hepatitis in patients who acquire hepatitis B virus infection in childhood.
Gastroenterology. 1990 Sep;99(3):805-10. doi: 10.1016/0016-5085(90)90972-4.
6
Liver cirrhosis associated with chronic hepatitis B virus infection in childhood.儿童期慢性乙型肝炎病毒感染相关的肝硬化
J Pediatr. 1986 Feb;108(2):224-7. doi: 10.1016/s0022-3476(86)80987-8.
7
Spontaneous reactivation of hepatitis B virus infection in patients with chronic type B hepatitis.慢性乙型肝炎患者中乙型肝炎病毒感染的自发再激活
Liver. 1990 Jun;10(3):141-6. doi: 10.1111/j.1600-0676.1990.tb00449.x.
8
Long-term follow-up of 60 patients with chronic hepatitis B. I. Seroconversion in the hepatitis B e-system, frequency of delta infection and histological outcome.60例慢性乙型肝炎患者的长期随访。I. 乙肝e系统的血清学转换、丁型感染频率及组织学转归
Liver. 1986 Feb;6(1):7-12. doi: 10.1111/j.1600-0676.1986.tb00261.x.
9
Reactivation of hepatitis B virus in anti-HBe-positive chronic active type B hepatitis: molecular and immunohistochemical studies.抗HBe阳性慢性活动性乙型肝炎中乙肝病毒的再激活:分子与免疫组化研究
Hepatogastroenterology. 1988 Feb;35(1):17-21.
10
[HBe antigen and B virus DNA in patients with chronic active hepatitis].[慢性活动性肝炎患者的乙肝e抗原与乙肝病毒DNA]
Gastroenterol Clin Biol. 1986 Nov;10(11):744-7.

引用本文的文献

1
Viral hepatitis B: clinical and epidemiological characteristics.乙型病毒性肝炎:临床与流行病学特征
Cold Spring Harb Perspect Med. 2014 Oct 30;4(12):a024935. doi: 10.1101/cshperspect.a024935.
2
Panaxadiol and panaxatriol derivatives as anti-hepatitis B virus inhibitors.人参二醇和人参三醇衍生物作为抗乙型肝炎病毒抑制剂
Nat Prod Bioprospect. 2014 Jun;4(3):163-74. doi: 10.1007/s13659-014-0018-2. Epub 2014 May 13.
3
Influencing Factors on the Outcome and Prognosis of Patients With HBV Infction: Seven Years Follow-up.乙型肝炎病毒感染患者结局和预后的影响因素:七年随访
Hepat Mon. 2013 Jul 8;13(7):e8743. doi: 10.5812/hepatmon.8743. eCollection 2013.
4
Globulin-platelet model predicts minimal fibrosis and cirrhosis in chronic hepatitis B virus infected patients.球蛋白-血小板模型预测慢性乙型肝炎病毒感染患者的最小纤维化和肝硬化。
World J Gastroenterol. 2012 Jun 14;18(22):2784-92. doi: 10.3748/wjg.v18.i22.2784.
5
Association between Hepatitis B Virus X Gene Mutations and Clinical Status in Patients with Chronic Hepatitis B Infection.乙型肝炎病毒 X 基因变异与慢性乙型肝炎感染患者临床状态的关系。
Gut Liver. 2011 Mar;5(1):70-6. doi: 10.5009/gnl.2011.5.1.70. Epub 2011 Mar 16.
6
Characteristics of treatment naïve chronic hepatitis B in Bangladesh: younger populations are more affected; HBeAg-negatives are more advanced.孟加拉国初治慢性乙型肝炎的特征:年轻人群受影响更大;HBeAg阴性患者病情更严重。
Saudi J Gastroenterol. 2008 Jan;14(1):15-9. doi: 10.4103/1319-3767.37796.
7
Natural course, therapeutic options and economic evaluation of therapies for chronic hepatitis B.慢性乙型肝炎的自然病程、治疗选择及治疗的经济学评估
Drugs. 2006;66(14):1831-51. doi: 10.2165/00003495-200666140-00005.
8
A preliminary benefit-risk assessment of lamivudine for the treatment of chronic hepatitis B virus infection.拉米夫定治疗慢性乙型肝炎病毒感染的初步效益-风险评估。
Drug Saf. 2002;25(7):497-510. doi: 10.2165/00002018-200225070-00004.
9
Long-term clinical remission induced by corticosteroid withdrawal therapy (CSWT) in patients with chronic hepatitis B infection: a prospective randomized controlled trial--CSWT with and without follow-up interferon-alpha therapy.皮质类固醇撤药疗法(CSWT)诱导慢性乙型肝炎感染患者实现长期临床缓解:一项前瞻性随机对照试验——有和没有后续干扰素-α治疗的CSWT
Dig Dis Sci. 2002 Feb;47(2):405-14. doi: 10.1023/a:1013742727165.
10
Preliminary results of Thymosin-a1 versus interferon-alpha-treatment in patients with HBeAg negative and serum HBV DNA positive chronic hepatitis B.胸腺肽α1与α干扰素治疗HBeAg阴性且血清HBV DNA阳性慢性乙型肝炎患者的初步结果
World J Gastroenterol. 2001 Jun;7(3):407-10. doi: 10.3748/wjg.v7.i3.407.